Moody National Bank Trust Division Has $10.43 Million Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Moody National Bank Trust Division lifted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 0.7% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 22,247 shares of the company’s stock after acquiring an additional 154 shares during the period. Eli Lilly and Company makes up 0.7% of Moody National Bank Trust Division’s holdings, making the stock its 12th biggest holding. Moody National Bank Trust Division’s holdings in Eli Lilly and Company were worth $10,433,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the stock. Silicon Valley Capital Partners bought a new stake in Eli Lilly and Company in the 1st quarter worth about $25,000. Bogart Wealth LLC grew its holdings in shares of Eli Lilly and Company by 193.3% in the first quarter. Bogart Wealth LLC now owns 88 shares of the company’s stock valued at $30,000 after acquiring an additional 58 shares in the last quarter. Laffer Tengler Investments purchased a new stake in shares of Eli Lilly and Company during the first quarter valued at approximately $33,000. Tanglewood Legacy Advisors LLC bought a new stake in Eli Lilly and Company during the fourth quarter worth $37,000. Finally, Freedom Wealth Alliance LLC purchased a new position in Eli Lilly and Company in the fourth quarter worth $37,000. Institutional investors and hedge funds own 81.38% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the company. Barclays lifted their target price on Eli Lilly and Company from $500.00 to $590.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 9th. JPMorgan Chase & Co. boosted their target price on shares of Eli Lilly and Company from $510.00 to $600.00 and gave the company an “overweight” rating in a research note on Wednesday, August 9th. HSBC started coverage on shares of Eli Lilly and Company in a research note on Friday, July 14th. They set a “buy” rating and a $560.00 price target for the company. Bank of America upped their price objective on Eli Lilly and Company from $500.00 to $600.00 in a research note on Wednesday, August 9th. Finally, Royal Bank of Canada upped their price target on Eli Lilly and Company from $490.00 to $580.00 and gave the company an “outperform” rating in a research report on Tuesday, August 8th. One analyst has rated the stock with a sell rating, one has given a hold rating and twenty have given a buy rating to the stock. According to MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus price target of $532.78.

Insider Activity at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 37,660 shares of Eli Lilly and Company stock in a transaction dated Monday, August 28th. The stock was sold at an average price of $546,751.75, for a total value of $20,590,670,905.00. Following the transaction, the insider now owns 100,275,279 shares in the company, valued at $54,825,684,274,988.30. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, major shareholder Lilly Endowment Inc sold 37,660 shares of Eli Lilly and Company stock in a transaction on Monday, August 28th. The shares were sold at an average price of $546,751.75, for a total value of $20,590,670,905.00. Following the transaction, the insider now directly owns 100,275,279 shares of the company’s stock, valued at $54,825,684,274,988.30. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CAO Donald A. Zakrowski sold 600 shares of the firm’s stock in a transaction on Monday, August 21st. The stock was sold at an average price of $546.51, for a total transaction of $327,906.00. Following the completion of the sale, the chief accounting officer now directly owns 5,378 shares in the company, valued at approximately $2,939,130.78. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,010,309 shares of company stock valued at $21,095,701,670. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $575.66 on Friday. Eli Lilly and Company has a 52-week low of $296.32 and a 52-week high of $601.84. The company has a fifty day moving average of $510.09 and a 200-day moving average of $435.73. The company has a market capitalization of $546.47 billion, a P/E ratio of 80.06, a P/E/G ratio of 2.47 and a beta of 0.32. The company has a debt-to-equity ratio of 1.63, a quick ratio of 0.87 and a current ratio of 1.13.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Tuesday, August 8th. The company reported $2.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.98 by $0.13. The firm had revenue of $8.31 billion during the quarter, compared to analyst estimates of $7.58 billion. Eli Lilly and Company had a return on equity of 65.00% and a net margin of 22.01%. The company’s revenue was up 28.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.25 earnings per share. As a group, equities research analysts predict that Eli Lilly and Company will post 9.84 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 8th. Stockholders of record on Tuesday, August 15th were issued a $1.13 dividend. The ex-dividend date was Monday, August 14th. This represents a $4.52 dividend on an annualized basis and a dividend yield of 0.79%. Eli Lilly and Company’s payout ratio is 62.87%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.